Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON44762
NL-OMON44762
Completed
Not Applicable

Prevention of breast cancer in high risk women by monitoring microrna expression in nipple aspirate fluid. - MicroRNA expression in nipple aspirate fluid.

niversitair Medisch Centrum Utrecht0 sites720 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbreast cancerbreast carcinoma100836241000629110006232

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
breast cancer
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
720
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • •\- Germline BRCA1 or BRCA2 mutation
  • •\- A \> 20% lifetime risk of developing breast cancer
  • •\- Previous DCIS/invasive breast cancer

Exclusion Criteria

  • •\-Bilateral ablative breast surgery
  • •\-Bilateral breast reduction with nipple graft
  • •\-Pregnancy or lactating
  • •\-Active breast infection
  • •\-Disseminated disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerBreast CancerCancer - Breast
ACTRN12615000161527Hellenic Cooperative Oncology Group1,000
Completed
Not Applicable
Investigation of the prognostic role of protein expression, mRNA levels, gene amplification and mutation of key cellular elements in patients with breast cancer treated with dose-dense sequential adjuvant chemotherapyBreast CancerCancer - Breast
ACTRN12616001043426Hellenic Cooperative Oncology Group1,060
Completed
Phase 3
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)
ACTRN12611000506998Hellenic Cooperative Oncology Group600
Completed
Not Applicable
A study to identify the risk factors of Breast Cancer among Indian Wome
CTRI/2011/07/001872I1,200
Completed
Not Applicable
My Lifestyle Intervention of Food and ExerciseBreast Cancer
NCT01630499University of Florida87